Sonata Software reports PAT of Rs 62 crore for Q4FY20
Sonata Software reports PAT of Rs 62 crore for Q4FY20

Sonata Software reports PAT of Rs 62 crore for Q4FY20

Amir Shaikh Article rating: 2.8

Sonata Software reported its fourth quarter result of FY20 on Monday. Its consolidated revenue for the quarter came in at Rs 928.68 crore, registering decline of 24.92 per cent QoQ

Ten stocks close to their 52-week low
Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

DSIJ Intelligence Article rating: 3.6

The market opened in the red on May 12, 2020. The previous trading session witnessed the Sensex going down by 81.48 points to end at 31,561.22 and the Nifty was down 12.3 points to close at 9,239.20.

Seamec secures DSV charter with L&T; gets NoA from HAL Offshore
Seamec secures DSV charter with L&T; gets NoA from HAL Offshore

Seamec secures DSV charter with L&T; gets NoA from HAL Offshore

Avalokita Pandey Article rating: 2.4

Seamec Limited announced that it has secured a contract with construction engineering company, L&T Hydrocarbon Engineering for the deployment of its diving support vessel (DSV) named-Seamec Princess for working at Mumbai High Offshore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 4.1

The market opened in the red on May 12, 2020, overall volumes in futures & options currently stand at 1,61 crore contracts with a turnover of Rs. 8,29,845.86 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.3

The market opened in the red on May 12, 2020, overall volumes in futures & options currently stand at 1,61 crore contracts with a turnover of Rs. 8,29,845.86 crore.

Glenmark Pharma begins phase 3 clinical trial on antiviral tablet
Glenmark Pharma begins phase 3 clinical trial on antiviral tablet

Glenmark Pharma begins phase 3 clinical trial on antiviral tablet

Apurva Joshi Article rating: 3.5

Glenmark Pharmaceuticals Limited has initiated phase 3 clinical trials in India on antiviral tablet-Favipiravir, for which it had received an approval from India’s drug regulator-DCGI in late April. Glenmark is the first company in India to initiate phase 3 clinical trials on Favipiravir for COVID-19 patients in India.

Ashok Leyland to consider fundraising this week
Ashok Leyland to consider fundraising this week

Ashok Leyland to consider fundraising this week

Avalokita Pandey Article rating: 3.6

Indian automobile manufacturer, Ashok Leyland, announced that it is planning to raise Rs 300 crore through the issuance of redeemable, non-convertible debentures (NCDs) on a private placement basis.

Index trend and stocks in action on May 12, 2020
Index trend and stocks in action on May 12, 2020

Index trend and stocks in action on May 12, 2020

DSIJ Intelligence-3 Article rating: 5.0

The zone of 9,188-9,240 is a crucial support level as 38.2 per cent retracement level and 20-DMA is placed in this region. A move below this level could take Nifty towards 8,972 levels in the short-term. Stocks in news: IND-Swift Laboratories, Ashok Leyland, InterGlobe Aviation.

Soft opening on cards!
Soft opening on cards!

Soft opening on cards!

DSIJ Intelligence-3 Article rating: 5.0

Markets worldwide have been gripped by fear of the viral infection resurging as report suggested that new Coronavirus cases have been found in countries such as China and South Korea. This pessimism is likely to attack Dalal Street and hence, SGX Nifty is indicating a negative start as it is down by 68 points at 9,147 level.

RSS
First30213022302330243026302830293030Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR